Cullinan Oncology Inc reports results for the quarter ended in December - Earnings Summary

Cullinan Therapeutics

14/03/2024 12:51

* Cullinan Oncology Inc  CGEM.OQ  reported a quarterly
adjusted
loss of 54 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -59 cents.  The mean expectation of
seven analysts for the quarter was for a loss of 96 cents per
share. Wall Street expected results to range from -100 cents
to -91 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cullinan Oncology Inc's reported EPS for the quarter was a
loss
of 54 cents​.
    * The company reported a quarterly loss of $23.8 million.
    * Cullinan Oncology Inc shares had risen by 66.6% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cullinan Oncology
Inc is $25.00 
This summary was machine generated from LSEG data March 14 at
12:50 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.96          -0.54          Beat
 Sep. 30 2023      -0.92          -0.91          Beat
 Jun. 30 2023      -0.97          -0.82          Beat
 Mar. 31 2023      -0.98          -1.42          Missed